Groundbreaking New Alzheimer's Drug Slows Progression Of The Disease, Finds Study
NDTV
The medication had a successful clinical trial and is expected to be approved by the Food and Drug Administration this fall.
A new and powerful drug that has been found to slow the progress of Alzheimer's has been hailed as a ‘turning point' in the fight against the disease, the New York Post reported. According to the results of a late-stage clinical trial, the experimental Alzheimer's drug called Donanemab from drugmaker Eli Lilly helped slow cognitive decline in patients in the early stages of the illness.
The medication had a successful clinical trial and is expected to be approved by the Food and Drug Administration this fall. As per Metro, the drug targets the build-up of amyloid protein in the brain and was found to slow ‘clinical decline' in patients by up to 35%.
When the results were combined for people who had different levels of this protein, there was a 22.3% slowing in disease progression.
